▶ 調査レポート

グルカゴン様ペプチド-1(GLP-1)アゴニストの世界及び中国市場

• 英文タイトル:Global and China Glucagon Like Peptide-1 (GLP-1) Agonists Market Insights, Forecast to 2027

QYResearchが調査・発行した産業分析レポートです。グルカゴン様ペプチド-1(GLP-1)アゴニストの世界及び中国市場 / Global and China Glucagon Like Peptide-1 (GLP-1) Agonists Market Insights, Forecast to 2027 / QY2108PAL8839資料のイメージです。• レポートコード:QY2108PAL8839
• 出版社/出版日:QYResearch / 2021年7月
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、137ページ
• 納品方法:Eメール(納期:1日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥585,000 (USD3,900)▷ お問い合わせ
  Multi User¥877,500 (USD5,850)▷ お問い合わせ
  Enterprise License¥1,170,000 (USD7,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
QYResearch社発行の当調査資料ではグローバルにおけるグルカゴン様ペプチド-1(GLP-1)アゴニストの市場規模(2016年-2027年)と動向についてまとめました。中国市場については主要プレイヤーの市場シェア、グルカゴン様ペプチド-1(GLP-1)アゴニストの種類別市場規模(エキセナチド、リラグルチド、リキシセナチド、アルビグルチド、デュラグルチド)、用途別市場規模(病院、薬局、その他)も掲載しています。他に、北米・アメリカ市場、ヨーロッパ市場、アジア太平洋・日本市場、中南米市場、中東・アフリカ市場の市場規模、グローバル市場機会・課題・リスク要因、バリューチェーン・販売チャネル、主要プレイヤーの情報なども掲載しています。
・調査の概要
・調査のサマリー
・世界のグルカゴン様ペプチド-1(GLP-1)アゴニスト市場動向
・グローバル主要プレイヤーの競争状況・市場シェア
・世界におけるグルカゴン様ペプチド-1(GLP-1)アゴニストの種類別市場規模(2016年-2027年):エキセナチド、リラグルチド、リキシセナチド、アルビグルチド、デュラグルチド
・世界におけるグルカゴン様ペプチド-1(GLP-1)アゴニストの用途別市場規模(2016年-2027年):病院、薬局、その他
・グルカゴン様ペプチド-1(GLP-1)アゴニストの中国市場分析
- グルカゴン様ペプチド-1(GLP-1)アゴニストの中国市場規模(2016年-2027年)
- 中国におけるグルカゴン様ペプチド-1(GLP-1)アゴニストの主要プレイヤー別市場シェア
- 中国におけるグルカゴン様ペプチド-1(GLP-1)アゴニストの種類別市場規模:エキセナチド、リラグルチド、リキシセナチド、アルビグルチド、デュラグルチド
- 中国におけるグルカゴン様ペプチド-1(GLP-1)アゴニストの用途別市場規模:病院、薬局、その他
・グルカゴン様ペプチド-1(GLP-1)アゴニストの北米市場(2016年-2027年)
・グルカゴン様ペプチド-1(GLP-1)アゴニストのヨーロッパ市場(2016年-2027年)
・グルカゴン様ペプチド-1(GLP-1)アゴニストのアジア太平洋市場(2016年-2027年)
・グルカゴン様ペプチド-1(GLP-1)アゴニストの中南米市場(2016年-2027年)
・グルカゴン様ペプチド-1(GLP-1)アゴニストの中東・アフリカ市場(2016年-2027年)
・主要プレイヤーの情報:Novo Nordisk、AstraZeneca、Eli Lily、GSK、Sanofi、Bristol-Myers Squibb、Amylin
・市場機会・課題・リスク要因分析
・バリューチェーン・販売チャネル分析
・...

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry by 68% market shares.
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44%. The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28%.

Market Analysis and Insights: Global and China Glucagon Like Peptide-1 (GLP-1) Agonists Market
This report focuses on global and China Glucagon Like Peptide-1 (GLP-1) Agonists market.
In 2020, the global Glucagon Like Peptide-1 (GLP-1) Agonists market size was US$ 7781.9 million and it is expected to reach US$ 18650 million by the end of 2027, with a CAGR of 13.3% during 2021-2027. In China the Glucagon Like Peptide-1 (GLP-1) Agonists market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Glucagon Like Peptide-1 (GLP-1) Agonists Scope and Market Size
Glucagon Like Peptide-1 (GLP-1) Agonists market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Glucagon Like Peptide-1 (GLP-1) Agonists market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For China market, this report focuses on the Glucagon Like Peptide-1 (GLP-1) Agonists market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in China.

Segment by Type
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide

Segment by Application
Hospital
Pharmacy
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Amylin

レポート目次

1 Study Coverage
1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Product Introduction
1.2 Market by Type
1.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Type
1.2.2 Exenatied
1.2.3 Liraglutide
1.2.4 Lixisenatide
1.2.5 Albiglutide
1.2.6 Dulaglutide
1.3 Market by Application
1.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Application
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary
2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size, Estimates and Forecasts
2.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue 2016-2027
2.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales 2016-2027
2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists, Market Size by Region: 2016 VS 2021 VS 2027
2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Historical Market Size by Region (2016-2021)
2.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Retrospective Market Scenario in Sales by Region: 2016-2021
2.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Retrospective Market Scenario in Revenue by Region: 2016-2021
2.4 Glucagon Like Peptide-1 (GLP-1) Agonists Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Region (2022-2027)
2.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Region (2022-2027)

3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Competitor Landscape by Players
3.1 Global Top Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers by Sales
3.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Manufacturer (2016-2021)
3.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers by Revenue
3.2.1 Key Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Covered: Ranking by Revenue
3.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturers (2016-2021)
3.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Concentration Ratio (CR5 and HHI) (2016-2021)
3.2.5 Global Top 10 and Top 5 Companies by Glucagon Like Peptide-1 (GLP-1) Agonists Revenue in 2020
3.2.6 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Manufacturers
3.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Base Distribution, Product Types
3.4.1 Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Product Type
3.4.3 Date of International Manufacturers Enter into Glucagon Like Peptide-1 (GLP-1) Agonists Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2016-2027)
4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type (2016-2021)
4.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2016-2021)
4.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2016-2021)
4.1.3 Glucagon Like Peptide-1 (GLP-1) Agonists Average Selling Price (ASP) by Type (2016-2021)
4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Forecast by Type (2022-2027)
4.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Type (2022-2027)
4.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Type (2022-2027)
4.2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Average Selling Price (ASP) Forecast by Type (2022-2027)

5 Breakdown Data by Application (2016-2027)
5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application (2016-2021)
5.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2016-2021)
5.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2016-2021)
5.1.3 Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2016-2021)
5.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Forecast by Application (2022-2027)
5.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Application (2022-2027)
5.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Application (2022-2027)
5.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price Forecast by Application (2022-2027)

6 China by Players, Type and Application
6.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Market Size YoY Growth 2016-2027
6.1.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY Growth 2016-2027
6.1.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue YoY Growth 2016-2027
6.1.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Market Share in Global Market 2016-2027
6.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Players (International and Local Players)
6.2.1 China Top Glucagon Like Peptide-1 (GLP-1) Agonists Players by Sales (2016-2021)
6.2.2 China Top Glucagon Like Peptide-1 (GLP-1) Agonists Players by Revenue (2016-2021)
6.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Historic Market Review by Type (2016-2021)
6.3.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2016-2021)
6.3.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2016-2021)
6.3.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2016-2021)
6.4 China Glucagon Like Peptide-1 (GLP-1) Agonists Market Estimates and Forecasts by Type (2022-2027)
6.4.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Type (2022-2027)
6.4.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Type (2022-2027)
6.4.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Price Forecast by Type (2022-2027)
6.5 China Glucagon Like Peptide-1 (GLP-1) Agonists Historic Market Review by Application (2016-2021)
6.5.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2016-2021)
6.5.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2016-2021)
6.5.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2016-2021)
6.6 China Glucagon Like Peptide-1 (GLP-1) Agonists Market Estimates and Forecasts by Application (2022-2027)
6.6.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Application (2022-2027)
6.6.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Application (2022-2027)
6.6.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Price Forecast by Application (2022-2027)

7 North America
7.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size YoY Growth 2016-2027
7.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
7.2.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021)
7.2.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021)
7.2.3 U.S.
7.2.4 Canada

8 Asia Pacific
8.1 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size YoY Growth 2016-2027
8.2 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Region
8.2.1 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2016-2021)
8.2.2 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2016-2021)
8.2.3 China
8.2.4 Japan
8.2.5 South Korea
8.2.6 India
8.2.7 Australia
8.2.8 Australia
8.2.9 Indonesia
8.2.10 Thailand
8.2.11 Malaysia
8.2.12 Philippines
8.2.13 Vietnam

9 Europe
9.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size YoY Growth 2016-2027
9.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
9.2.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021)
9.2.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021)
9.2.3 Germany
9.2.4 France
9.2.5 U.K.
9.2.6 Italy

10 Latin America
10.1 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size YoY Growth 2016-2027
10.2 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
10.2.1 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021)
10.2.2 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021)
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina

11 Middle East and Africa
11.1 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
11.2.1 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021)
11.2.2 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021)
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E

12 Company Profiles
12.1 Novo Nordisk
12.1.1 Novo Nordisk Corporation Information
12.1.2 Novo Nordisk Description and Business Overview
12.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
12.1.5 Novo Nordisk Recent Development
12.2 AstraZeneca
12.2.1 AstraZeneca Corporation Information
12.2.2 AstraZeneca Description and Business Overview
12.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
12.2.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
12.2.5 AstraZeneca Recent Development
12.3 Eli Lily
12.3.1 Eli Lily Corporation Information
12.3.2 Eli Lily Description and Business Overview
12.3.3 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
12.3.5 Eli Lily Recent Development
12.4 GSK
12.4.1 GSK Corporation Information
12.4.2 GSK Description and Business Overview
12.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
12.4.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
12.4.5 GSK Recent Development
12.5 Sanofi
12.5.1 Sanofi Corporation Information
12.5.2 Sanofi Description and Business Overview
12.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
12.5.5 Sanofi Recent Development
12.6 Bristol-Myers Squibb
12.6.1 Bristol-Myers Squibb Corporation Information
12.6.2 Bristol-Myers Squibb Description and Business Overview
12.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
12.6.5 Bristol-Myers Squibb Recent Development
12.7 Amylin
12.7.1 Amylin Corporation Information
12.7.2 Amylin Description and Business Overview
12.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
12.7.5 Amylin Recent Development
12.11 Novo Nordisk
12.11.1 Novo Nordisk Corporation Information
12.11.2 Novo Nordisk Description and Business Overview
12.11.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
12.11.5 Novo Nordisk Recent Development

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends
13.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers
13.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges
13.4 Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Glucagon Like Peptide-1 (GLP-1) Agonists Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

List of Tables
Table 1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Exenatied
Table 3. Major Manufacturers of Liraglutide
Table 4. Major Manufacturers of Lixisenatide
Table 5. Major Manufacturers of Albiglutide
Table 6. Major Manufacturers of Dulaglutide
Table 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Application (2021-2027) & (K Units)
Table 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Region (K Units) & (US$ Million), 2016 VS 2021 VS 2027
Table 9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Regions (2016-2021) & (K Units)
Table 10. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Regions (2016-2021)
Table 11. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Regions (2016-2021) & (US$ Million)
Table 12. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Region (2022-2027) & (K Units)
Table 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share Forecast by Region (2022-2027)
Table 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share Forecast by Region (2022-2027)
Table 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Manufacturers (2016-2021) (K Units)
Table 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Manufacturers (2016-2021)
Table 18. Ranking of Global Top Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers by Revenue (US$ Million) in 2020
Table 19. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturers (2016-2021) (US$ Million)
Table 20. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Manufacturers (2016-2021)
Table 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
Table 22. Global Glucagon Like Peptide-1 (GLP-1) Agonists by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Glucagon Like Peptide-1 (GLP-1) Agonists as of 2020)
Table 23. Key Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Price (2016-2021) (USD/Unit)
Table 24. Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Product Type
Table 26. Date of International Manufacturers Enter into Glucagon Like Peptide-1 (GLP-1) Agonists Market
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2016-2021) (K Units)
Table 29. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Type (2016-2021)
Table 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2016-2021) (US$ Million)
Table 31. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2016-2021)
Table 32. Glucagon Like Peptide-1 (GLP-1) Agonists Average Selling Price (ASP) by Type (2016-2021) & (USD/Unit)
Table 33. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Type (2022-2027) & (K Units)
Table 34. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share Forecast by Type (2022-2027)
Table 35. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast V (2022-2027) & (US$ Million)
Table 36. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share Forecast by Type (2022-2027)
Table 37. Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Selling Price (ASP) Forecast by Type (2022-2027) & (USD/Unit)
Table 38. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2016-2021) (K Units)
Table 39. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Application (2016-2021)
Table 40. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2016-2021) (US$ Million)
Table 41. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Application (2016-2021)
Table 42. Glucagon Like Peptide-1 (GLP-1) Agonists Average Selling Price (ASP) by Application (2016-2021) & (USD/Unit)
Table 43. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Application (2022-2027) & (K Units)
Table 44. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share Forecast by Application (2022-2027)
Table 45. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 46. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share Forecast by Application (2022-2027)
Table 47. Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Selling Price (ASP) Forecast by Application (2022-2027) & (USD/Unit)
Table 48. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) of Key Companies (2016-2021)
Table 49. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Company (2016-2021)
Table 50. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) by Company (2016-2021)
Table 51. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Company (2016-2021)
Table 52. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) by Type (2016-2021)
Table 53. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Type (2016-2021)
Table 54. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) Market Share by Type (2016-2021)
Table 55. China Glucagon Like Peptide-1 (GLP-1) Agonists Price (USD/Unit) by Type (2016-2021)
Table 56. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) by Type (2022-2027)
Table 57. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Type (2022-2027)
Table 58. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) Market Share by Type (2022-2027)
Table 59. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2022-2027)
Table 60. China Glucagon Like Peptide-1 (GLP-1) Agonists Price (USD/Unit) by Type (2022-2027)
Table 61. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) by Application (2016-2021)
Table 62. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Application (2016-2021)
Table 63. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) Market Share by Application (2016-2021)
Table 64. China Glucagon Like Peptide-1 (GLP-1) Agonists Price (USD/Unit) by Application (2016-2021)
Table 65. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) by Application (2022-2027)
Table 66. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Application (2022-2027)
Table 67. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) Market Share by Application (2022-2027)
Table 68. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Application (2022-2027)
Table 69. China Glucagon Like Peptide-1 (GLP-1) Agonists Price (USD/Unit) by Application (2022-2027)
Table 70. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021) & (K Units)
Table 71. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2016-2021)
Table 72. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021) & (US$ Million)
Table 73. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2016-2021)
Table 74. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2016-2021) & (K Units)
Table 75. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2016-2021)
Table 76. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2016-2021) & (US$ Million)
Table 77. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2016-2021)
Table 78. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021) & (K Units)
Table 79. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2016-2021)
Table 80. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021) & (US$ Million)
Table 81. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2016-2021)
Table 82. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021) & (K Units)
Table 83. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2016-2021)
Table 84. Latin Americaa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021) & (US$ Million)
Table 85. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2016-2021)
Table 86. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021) & (K Units)
Table 87. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2016-2021)
Table 88. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021) & (US$ Million)
Table 89. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2016-2021)
Table 90. Novo Nordisk Corporation Information
Table 91. Novo Nordisk Description and Business Overview
Table 92. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 93. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 94. Novo Nordisk Recent Development
Table 95. AstraZeneca Corporation Information
Table 96. AstraZeneca Description and Business Overview
Table 97. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 98. AstraZeneca Product
Table 99. AstraZeneca Recent Development
Table 100. Eli Lily Corporation Information
Table 101. Eli Lily Description and Business Overview
Table 102. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 103. Eli Lily Product
Table 104. Eli Lily Recent Development
Table 105. GSK Corporation Information
Table 106. GSK Description and Business Overview
Table 107. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 108. GSK Product
Table 109. GSK Recent Development
Table 110. Sanofi Corporation Information
Table 111. Sanofi Description and Business Overview
Table 112. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 113. Sanofi Product
Table 114. Sanofi Recent Development
Table 115. Bristol-Myers Squibb Corporation Information
Table 116. Bristol-Myers Squibb Description and Business Overview
Table 117. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 118. Bristol-Myers Squibb Product
Table 119. Bristol-Myers Squibb Recent Development
Table 120. Amylin Corporation Information
Table 121. Amylin Description and Business Overview
Table 122. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 123. Amylin Product
Table 124. Amylin Recent Development
Table 125. Glucagon Like Peptide-1 (GLP-1) Agonists Market Trends
Table 126. Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers
Table 127. Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges
Table 128. Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints
Table 129. Glucagon Like Peptide-1 (GLP-1) Agonists Customers List
Table 130. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Glucagon Like Peptide-1 (GLP-1) Agonists Product Picture
Figure 2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type in 2020 & 2027
Figure 3. Exenatied Product Picture
Figure 4. Liraglutide Product Picture
Figure 5. Lixisenatide Product Picture
Figure 6. Albiglutide Product Picture
Figure 7. Dulaglutide Product Picture
Figure 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application in 2020 & 2027
Figure 9. Hospital
Figure 10. Pharmacy
Figure 11. Other
Figure 12. Glucagon Like Peptide-1 (GLP-1) Agonists Report Years Considered
Figure 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size, (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size 2016-2027 (US$ Million)
Figure 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales 2016-2027 (K Units)
Figure 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Market Share by Region: 2021 Versus 2027
Figure 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2016-2021)
Figure 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region in 2020
Figure 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2016-2021)
Figure 20. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region in 2020
Figure 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Manufacturer in 2020
Figure 22. The Top 10 and 5 Players Market Share by Glucagon Like Peptide-1 (GLP-1) Agonists Revenue in 2020
Figure 23. Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2016-2021)
Figure 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type in 2020
Figure 26. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2016-2021)
Figure 27. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type in 2020
Figure 28. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2016-2021)
Figure 29. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application in 2020
Figure 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2016-2021)
Figure 31. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application in 2020
Figure 32. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate 2016-2027 (K Units)
Figure 33. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate 2016-2027 (US$ Million)
Figure 34. China Glucagon Like Peptide-1 (GLP-1) Agonists Market Share in Global Market 2016-2027
Figure 35. China 5 and 10 Largest Glucagon Like Peptide-1 (GLP-1) Agonists Players Market Share by Revenue in Glucagon Like Peptide-1 (GLP-1) Agonists in 2020
Figure 36. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2016-2021)
Figure 37. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate by Type in 2016 & 2020
Figure 38. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Application (2016-2021)
Figure 39. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate by Application in 2016 & 2020
Figure 40. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate 2016-2021 (K Units)
Figure 41. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate 2016-2021 (US$ Million)
Figure 42. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country in 2020
Figure 43. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country in 2020
Figure 44. U.S. Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 45. U.S. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 47. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate 2016-2021 (K Units)
Figure 49. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate 2016-2021 (US$ Million)
Figure 50. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country in 2020
Figure 51. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country in 2020
Figure 52. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 53. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 54. France Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 55. France Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 56. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 57. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 58. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 59. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 60. Russia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 61. Russia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 62. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate 2016-2021 (K Units)
Figure 63. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate 2016-2021 (US$ Million)
Figure 64. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region in 2020
Figure 65. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region in 2020
Figure 66. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 67. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 68. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 69. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 70. South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 71. South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 72. India Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 73. India Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 74. Australia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 75. Australia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 76. Taiwan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 77. Taiwan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 78. Indonesia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 79. Indonesia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 80. Thailand Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 81. Thailand Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 82. Malaysia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 83. Malaysia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 84. Philippines Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 85. Philippines Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 86. Vietnam Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 87. Vietnam Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 88. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate 2016-2021 (K Units)
Figure 89. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate 2016-2021 (US$ Million)
Figure 90. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country in 2020
Figure 91. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country in 2020
Figure 92. Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 93. Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 94. Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 95. Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 96. Argentina Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 97. Argentina Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 98. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate 2016-2021 (K Units)
Figure 99. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate 2016-2021 (US$ Million)
Figure 100. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country in 2020
Figure 101. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country in 2020
Figure 102. Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 103. Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 104. Saudi Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 105. Saudi Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 106. U.A.E Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 107. U.A.E Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 108. Glucagon Like Peptide-1 (GLP-1) Agonists Value Chain
Figure 109. Channels of Distribution
Figure 110. Distributors Profiles
Figure 111. Bottom-up and Top-down Approaches for This Report
Figure 112. Data Triangulation
Figure 113. Key Executives Interviewed